drugset / Trial / NCT06872112
A Study Evaluating the Safety and Tolerability of Artesunate in Patients With Pulmonary Arterial Hypertension
NaSingle-groupOpen-labelTreatment
Summary
This is a 20-week, Phase 1, single-center, open-label, dose-escalation study evaluating the safety and tolerability of daily oral artesunate in patients with PAH.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2029-01-01
- Completion
- 2029-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Artesunate | Small molecule | 20 mg | Oral |
| Subject | Artesunate | Small molecule | 40 mg | Oral |
| Subject | Artesunate | Small molecule | 60 mg | Oral |